Skip to content

Study · Not a test of the peptide alone · 1993

1 result

Lack of effect of enalaprilat on the action of vasoactive intestinal polypeptide in the human forearm.

Cockcroft JR, Chowienczyk P, Elliott TG, Ritter JM

British journal of clinical pharmacology1 May 1993Cited by 2 (Europe PMC)

PMID8390278 (opens in a new tab)PMCIDPMC1381691 (opens in a new tab)DOI10.1111/j.1365-2125.1993.tb04179.x (opens in a new tab)PepBankPUB-08390278
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialMechanism

    In normal volunteers, local inhibition of vascular ACE did not change the effects of brachial-artery VIP infusion on forearm resistance vessels.

    In plain wordsIn healthy volunteers, blocking ACE in the forearm vessels did not change how VIP acted on those vessels.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeEffect of local ACE inhibition (enalaprilat) on VIP vasodilation in forearm resistance vessels
    Study

    n: not reported in source

    Comparator
    Without enalaprilat
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    This study has shown that inhibition of local vascular ACE does not interfere with the vascular effects of VIP on forearm resistance vessels when this peptide is infused into the brachial artery of normal volunteers.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.